Eshan U Patel1, Sunil S Solomon2, Gregory M Lucas3, Allison M McFall1, Aylur K Srikrishnan4, Muniratnam S Kumar4, Syed H Iqbal4, Shanmugam Saravanan4, Nandagopal Paneerselvam4, Pachamuthu Balakrishnan4, Oliver Laeyendecker5, David D Celentano1, Shruti H Mehta1. 1. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. 2. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: sss@jhmi.edu. 3. Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 4. YR Gaitonde Centre for AIDS Research and Education, Chennai, India. 5. Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Abstract
BACKGROUND: Population-level prevalence of detectable HIV viraemia (PDV) has been proposed as a metric for monitoring the population-level effectiveness of HIV treatment as prevention. We aimed to characterise temporal changes in PDV in people who inject drugs (PWID) and men who have sex with men (MSM) in India and evaluate community-level and individual-level associations with cross-sectional HIV incidence. METHODS: We did a serial cross-sectional study in which baseline (from Oct 1, 2012, to Dec 19, 2013) and follow-up (from Aug 1, 2016, to May 28, 2017) respondent-driven sampling (RDS) surveys were done in MSM (ten community sites) and PWID (12 community sites) across 21 cities in India. Eligible participants were those aged 18 years or older who provided informed consent and possessed a valid RDS referral coupon. Annualised HIV incidence was estimated with validated multiple-assay algorithms. PDV was calculated as the percentage of people with detectable HIV RNA (>150 copies per mL) in a community site. Community-level associations were determined by linear regression. Multivariable, multilevel Poisson regression was used to assess associations with recent HIV infection. FINDINGS: We recruited 21 990 individuals in the baseline survey and 21 726 individuals in the follow-up survey. The median community-level HIV incidence estimate increased from 0·9% (range 0·0-2·2) at baseline to 1·5% (0·5-3·0) at follow-up in MSM and from 1·6% (0·5-12·4) to 3·6% (0·0-18·4) in PWID. At the community-level, every 1 percentage point increase in baseline PDV and temporal change in PDV between surveys was associated with higher annualised HIV incidence at follow-up: for baseline PDV β=0·41 (95% CI 0·18-0·63) and for change in PDV β=0·52 (0·38-0·66). After accounting for individual-level risk factors, every 10 percentage point increase in baseline PDV and temporal change in PDV was associated with higher individual-level risk of recent HIV infection at follow-up: adjusted risk ratio 1·85 (95% CI 1·44-2·37) for baseline PDV and 1·81 (1·43-2·29) for change in PDV. INTERPRETATION: PDV was temporally associated with community-level and individual-level HIV incidence. These data support scale-up of treatment as prevention programmes to reduce HIV incidence and the programmatic use of PDV to monitor community HIV risk potential. FUNDING: US National Institutes of Health, Elton John AIDS Foundation.
BACKGROUND: Population-level prevalence of detectable HIV viraemia (PDV) has been proposed as a metric for monitoring the population-level effectiveness of HIV treatment as prevention. We aimed to characterise temporal changes in PDV in people who inject drugs (PWID) and men who have sex with men (MSM) in India and evaluate community-level and individual-level associations with cross-sectional HIV incidence. METHODS: We did a serial cross-sectional study in which baseline (from Oct 1, 2012, to Dec 19, 2013) and follow-up (from Aug 1, 2016, to May 28, 2017) respondent-driven sampling (RDS) surveys were done in MSM (ten community sites) and PWID (12 community sites) across 21 cities in India. Eligible participants were those aged 18 years or older who provided informed consent and possessed a valid RDS referral coupon. Annualised HIV incidence was estimated with validated multiple-assay algorithms. PDV was calculated as the percentage of people with detectable HIV RNA (>150 copies per mL) in a community site. Community-level associations were determined by linear regression. Multivariable, multilevel Poisson regression was used to assess associations with recent HIV infection. FINDINGS: We recruited 21 990 individuals in the baseline survey and 21 726 individuals in the follow-up survey. The median community-level HIV incidence estimate increased from 0·9% (range 0·0-2·2) at baseline to 1·5% (0·5-3·0) at follow-up in MSM and from 1·6% (0·5-12·4) to 3·6% (0·0-18·4) in PWID. At the community-level, every 1 percentage point increase in baseline PDV and temporal change in PDV between surveys was associated with higher annualised HIV incidence at follow-up: for baseline PDV β=0·41 (95% CI 0·18-0·63) and for change in PDV β=0·52 (0·38-0·66). After accounting for individual-level risk factors, every 10 percentage point increase in baseline PDV and temporal change in PDV was associated with higher individual-level risk of recent HIV infection at follow-up: adjusted risk ratio 1·85 (95% CI 1·44-2·37) for baseline PDV and 1·81 (1·43-2·29) for change in PDV. INTERPRETATION: PDV was temporally associated with community-level and individual-level HIV incidence. These data support scale-up of treatment as prevention programmes to reduce HIV incidence and the programmatic use of PDV to monitor community HIV risk potential. FUNDING: US National Institutes of Health, Elton John AIDS Foundation.
Authors: Martien W Borgdorff; Daniel Kwaro; David Obor; George Otieno; Viviane Kamire; Frederick Odongo; Patrick Owuor; Jacques Muthusi; Lisa A Mills; Rachael Joseph; Mary E Schmitz; Peter W Young; Emily Zielinski-Gutierrez; Kevin M De Cock Journal: Lancet HIV Date: 2018-04-09 Impact factor: 12.767
Authors: Sunil S Solomon; Shruti H Mehta; Aylur K Srikrishnan; Canjeevaram K Vasudevan; Allison M Mcfall; Pachamuthu Balakrishnan; Santhanam Anand; Panneerselvam Nandagopal; Elizabeth L Ogburn; Oliver Laeyendecker; Gregory M Lucas; Suniti Solomon; David D Celentano Journal: AIDS Date: 2015-03-27 Impact factor: 4.177
Authors: Don C Des Jarlais; Vana Sypsa; Jonathan Feelemyer; Adrian O Abagiu; Vic Arendt; Dita Broz; Daniel Chemtob; Carole Seguin-Devaux; Joan M Duwve; Margaret Fitzgerald; David J Goldberg; Angelos Hatzakis; Raluca E Jipa; Eugene Katchman; Eamon Keenan; Ibrahim Khan; Stephanie Konrad; Andrew McAuley; Stuart Skinner; Lucas Wiessing Journal: Lancet HIV Date: 2020-06 Impact factor: 12.767
Authors: Sunil S Solomon; Suniti Solomon; Allison M McFall; Aylur K Srikrishnan; Santhanam Anand; Vinita Verma; Canjeevaram K Vasudevan; Pachamuthu Balakrishnan; Elizabeth L Ogburn; Lawrence H Moulton; Muniratnam S Kumar; Kuldeep Singh Sachdeva; Oliver Laeyendecker; David D Celentano; Gregory M Lucas; Shruti H Mehta Journal: Lancet HIV Date: 2019-04-02 Impact factor: 12.767
Authors: Don C Des Jarlais; Kamyar Arasteh; Courtney McKnight; Jonathan Feelemyer; Aimée N C Campbell; Susan Tross; Lou Smith; Hannah L F Cooper; Holly Hagan; David Perlman Journal: Am J Public Health Date: 2016-01-21 Impact factor: 9.308
Authors: Joseph Makhema; Kathleen E Wirth; Molly Pretorius Holme; Tendani Gaolathe; Mompati Mmalane; Etienne Kadima; Unoda Chakalisa; Kara Bennett; Jean Leidner; Kutlo Manyake; Atang M Mbikiwa; Selebaleng V Simon; Rona Letlhogile; Kutlwano Mukokomani; Erik van Widenfelt; Sikhulile Moyo; Refeletswe Lebelonyane; Mary G Alwano; Kathleen M Powis; Scott L Dryden-Peterson; Coulson Kgathi; Vlad Novitsky; Janet Moore; Pamela Bachanas; William Abrams; Lisa Block; Shenaaz El-Halabi; Tafireyi Marukutira; Lisa A Mills; Connie Sexton; Elliot Raizes; Simani Gaseitsiwe; Hermann Bussmann; Lillian Okui; Oaitse John; Roger L Shapiro; Sherri Pals; Haben Michael; Michelle Roland; Victor DeGruttola; Quanhong Lei; Rui Wang; Eric Tchetgen Tchetgen; M Essex; Shahin Lockman Journal: N Engl J Med Date: 2019-07-18 Impact factor: 176.079
Authors: Oliver Laeyendecker; Jacob Konikoff; Douglas E Morrison; Ronald Brookmeyer; Jing Wang; Connie Celum; Charles S Morrison; Quarraisha Abdool Karim; Audrey E Pettifor; Susan H Eshleman Journal: J Int AIDS Soc Date: 2018-02 Impact factor: 5.396
Authors: Alain Vandormael; Adam Akullian; Mark Siedner; Tulio de Oliveira; Till Bärnighausen; Frank Tanser Journal: Nat Commun Date: 2019-12-02 Impact factor: 14.919
Authors: Eshan U Patel; Sunil S Solomon; Allison M McFall; Neia Prata Menezes; Cecília Tomori; Aylur K Srikrishnan; Muniratnam S Kumar; David D Celentano; Gregory M Lucas; Shruti H Mehta Journal: AIDS Date: 2022-06-22 Impact factor: 4.632
Authors: Steven J Clipman; Sunil S Solomon; Aylur K Srikrishnan; Allison M McFall; Selvamurthi Gomathi; Shanmugam Saravanan; Santhanam Anand; Canjeevaram K Vasudevan; Muniratnam S Kumar; David D Celentano; Shruti H Mehta; Gregory M Lucas Journal: Open Forum Infect Dis Date: 2022-09-17 Impact factor: 4.423
Authors: Shelley N Facente; Eduard Grebe; Andrew D Maher; Douglas Fox; Susan Scheer; Mary Mahy; Shona Dalal; David Lowrance; Kimberly Marsh Journal: JMIR Public Health Surveill Date: 2022-03-11